NextGen Biomed 2026

Register for the event

NextGen Biomed 2026

NextGen Biomed is an ecosystem of events and channels that enable the biologics drug discovery & development community to move as one. They are an industry movement for the entire biologics R&D value chain, with more than 30,000 experts and six industry platforms in one.

Meet our colleagues in London from March 24 – 25. Join our presentation on Day 1 – You will find more information below.

See who is attending from Bachem - Booth #26

Vera D'Aloisio

Business Development Manager

Mathias Beysard

Business Development Manager Oligonucleotides

See who from Bachem is attending and giving a company presentation on-site

2D-LC-MS: Peak purity determination for denaturing SAX oligonucleotide methods

Day 1, Track 7, 15:10

Oligonucleotides are emerging new therapeutic entities and reliable selective analytical methods to determine their purity and related impurities are critical. Strong anion exchange (SAX) liquid chromatography (LC) methods are often used as an orthogonal method to well established ion-pairing reversed phase (IP-RP) methods, particularly for phosphorothioate oligonucleotides. However, the non-volatile eluents of SAX methods deem them not MS-compatible and are hindering direct peak purity analysis.

In this presentation, a novel 2D-LC-MS approach developed at Bachem will be described that allows the evaluation of peak purity by using SAX methods in combination with IP-RP and high-resolution MS.

SPEAKER

Marion Fresch

Senior Scientist QC

Marion Fresch is Senior scientist in the QC Early Phase department at Bachem AG. She joined the company in 2021, specializing in HPLC method development, validations, forced degradation studies, release analytics, and stability testing for oligonucleotide NCE projects. Marion holds a PhD in analytical food chemistry from the university of Stuttgart where her interest in patient health grew as she was working on food allergen analysis.

Upcoming Events